Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Galderma R&D
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participant has a diagnosis of plaque-type psoriasis up to 20% of body surface area (BSA) involved excluding the scalp, with a Global Severity Score of at least 3 (moderate) at Screening
Participant presents with a representative target lesion that is at least 16 cm² in area, is located on the non-bony areas of the skin, has a Scaling Score up to 2 (moderate), has a DSS of at least 4
You may not be if
Other type of psoriasis (other than plaque)
Significant abnormal lab findings
Hypercalcemia
Clareo Health | Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
